Antibacterial drug discovery in the 21st century

Clinical Microbiology and Infection, Supplement

Volumn 10, Issue 4, 2004, Pages 10-17

  Bush, Karen ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anti infective; Antibacterial agents; Antibiotics; Drug discovery; Research; Resistance

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; AMIKACIN; AMOXICILLIN; AMPICILLIN; ANALGESIC AGENT; ANESTHETIC AGENT; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; AZTREONAM; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CEFACLOR; CEFALEXIN; CEFALORIDINE; CEFALOTIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CENTRAL NERVOUS SYSTEM AGENTS; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; CYTOCHROME P450; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; GARENOXACIN; GASTROINTESTINAL AGENT; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; HEMATOLOGIC AGENT; ICLAPRIM; IMIPENEM; IMMUNOGLOBULIN; IVERMECTIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MICONAZOLE; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; MOXIFLOXACIN; NALIDIXIC ACID; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; SPARFLOXACIN; STREPTOMYCIN; SULBACTAM; TAZOBACTAM; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL STUDY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG INDUSTRY; DRUG MARKETING; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; ECONOMIC DEVELOPMENT; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HISTORY OF MEDICINE; HUMAN; KLEBSIELLA PNEUMONIAE; NEPHROTOXICITY; ONCHOCERCIASIS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TUBERCULOSIS; BACTERIUM; DRUG DESIGN; DRUG EFFECT; ECONOMICS; FORECASTING; HISTORY; PHARMACEUTICS; REVIEW; SYNTHESIS; LONG TERM CARE; SOCIAL ASPECT;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; FORECASTING; HISTORY, 21ST CENTURY; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 16644389654     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1465-0691.2004.1005.x     Document Type: Article

References (40)

1. Diggins FW. The discovery of penicillin: so many get it wrong. Biologist 2000; 47: 115-9.
2. Schatz A, Bugie E, Waksman SA. Selman Abraham Waksman, PhD, 22 July 1888-16 August 1973. Streptomycin reported. Ann Intern Med 1973, 79: 678.
3. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 146: 837.
4. Davies JE. Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Foundation Symp 1997; 207: 15-27; discussion 27-35.
5. Perine PL, Schalla W, Siegel MS, et al. Evidence for two distinct types of penicillinase-producing Neisseria gonorrhoeae. Lancet 1977; 2: 993-7.
6. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001; 9: 486-93.
7. 3. Peterson LR. Quinolone resistance in clinical practice: occurrence and importance. In: Quinolone Antimicrobial Agents, 2nd Edn. (eds Hooper, DC, Wolfson, JS American Society for Microbiology): 119-37.
8. Lacey RW, Mitchell AA. Gentamicin-resistant Staphylococcus aureus. Lancet 1969; 2: 1425-6.
9. Then RL, Angehrn P. Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob Agents Chemother 1982; 21: 711-7.
10. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
11. Clemett D, Markham A, Linezolid. Drugs 2000; 59: 815-27; discussion 828.
12. Bozdogan B, Appelbaum PC. Oxazolidinones activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004; 23: 113-9.
13. Bush K. The evoution of β-lactamases. In: Antibiotic Resistance: Origins, Evolution, Selection and Spread. (eds Chadwick, DJ, Goode, J.). John Wiley & Sons 1997,152-66. Ciba Foundation Symposium, Vol. 207.
14. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-laclam antibiotics. Clinic Infect Dis 1997; 24: S19-45.
15. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
16. Liassine N, Auckenthaler R, Descombes MC, Bes M, Vandenesch F, Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol 2004; 42: 825-8.
17. Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10(Suppl. 4): 1-9.
18. Porschen RK. Legionnaires' disease more on staining and isolation of Legionella pneumophila. N Engl J Med 1979; 300: 369-70.
19. Chen SC, Gilbert GL. Cat scratch disease: past and present. J Paediat Child Health 1994; 30: 467-9.
20. Marshall Bj. The Campylobacter pylori story. Scand J Gastroenterol 1988; 146(Suppl): 58-66.
21. Anderson JL, Muhlestein JB, Carlquist J et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serologicat evidence for Chlamydia pneumoniae infection: The AZithromycin in Coronary Artery Disease: Elimination if Myocardial Infection with Chlamydia (ACADEMIC) study. [See comment]. Circulation 1999; 99: 1540-7.
22. Selzman CH, Netea MG, Zimmerman N4A, et al. Atherogenic effects of Chlamydia pneunioniae: refuting the innocent bystander hypothesis. J Thoracic Cardiovas Surg 2003, 126: 688-93.
23. Ronchetti F, Ronchetti R, Guglielmi F, et al. Detection of Chlamydia pneumoniae in cholesteatoma tissue: any pathogenetic role? Otol Neurotol 2003; 24: 353-7.
24. Little CS, Hammond CJ, Machityre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Adzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 2004; 25: 419-29.
25. Dalton R. Genetic sleuths rush to identify anthrax strains in mail attacks. Nature 2001; 413: 657-8.
26. Brook I, Elliott TB, Pryor HI, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolicles and quinolones. Int J Antimicrob Agents 2001; 18: 559-62.
27. Shen Y, Zhukovskaya NL, Zimmer MI, et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infc-Jion. Proc Natl Acad Sci USA 2004; 101: 3242-7.
28. Ellis R, Lancaster DJ, Cephawhatchamacallums. N Engl J Med 1989; 320: 872.
29. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Melec Pharmacol 2001; 59: 122-6.
30. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003, 51: ii45-53.
31. Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002; 62: 1771-804.
32. Dimasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Therapeutics 2001; 69: 297-307.
33. Keim KL, Calcagno J, Leventer SM, Harris HW. Unlocking the value of failed CNS trials. Curr Drug Disc 2003; 3: 29-33.
34. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics 1995; 7: 152-69.
35. Projan SJ. Infectious diseases in the 21st century: increasing threats, fewer new treatments and a premium on prevention. Curr Opin Pharmacol 2003; 3: 457-8.
36. IMS Health World Review 2003.
37. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econom 2003; 22: 151-85.
38. Bush K. Why it is important to continue antibacterial drug discovery. ASM News 2004; 70: 282-7.
39. Projan S, Shlaes D, Update: antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 2004; 10(Suppl. 4): 18-22.
40. Powers JH. Antimicrobial drug development the past, the present, and the future. Clin Microbiol Infect 2004; 10(Suppl. 4): 23-30.